• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Altria Group (MO)'s First FDA‑Cleared on! PLUS Pouches Mean For Shareholders

    Simply Wall St·01/06/2026 06:17:17
    語音播報
    • In late 2025, Altria Group received FDA marketing authorization for six of its on! PLUS nicotine pouch products, the first approvals granted under the agency’s expedited Premarket Tobacco Product Applications program.
    • The decision marks a meaningful step in Altria’s shift toward reduced-risk oral nicotine offerings, aiming to counter ongoing declines in traditional cigarette volumes while sustaining its capital return profile.
    • Next, we’ll examine how this FDA authorization for on! PLUS pouches could influence Altria’s investment narrative and forward-looking risk balance.

    Find companies with promising cash flow potential yet trading below their fair value.

    Altria Group Investment Narrative Recap

    To own Altria today, you have to believe its pivot toward reduced risk products can offset ongoing cigarette volume declines while still supporting substantial cash returns. The FDA’s marketing authorization for six on! PLUS nicotine pouches directly supports that thesis in the near term, while the biggest risk remains whether newer oral and vapor products can gain enough legal, profitable scale in the face of regulatory and competitive pressures.

    Against this backdrop, Altria’s recent decision to maintain its regular quarterly dividend of US$1.06 per share stands out as particularly relevant. For many shareholders, the dividend and buyback program are central to the investment case, and the new FDA approval for on! PLUS products sits squarely in the debate over how durable that capital return profile can be if cigarette revenues continue to erode.

    Yet behind the steady dividend, investors should be aware that...

    Read the full narrative on Altria Group (it's free!)

    Altria Group’s narrative projects $20.3 billion revenue and $9.1 billion earnings by 2028. This requires a 0.1% yearly revenue decline and a $1.1 billion earnings decrease from $10.2 billion today.

    Uncover how Altria Group's forecasts yield a $63.83 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    MO 1-Year Stock Price Chart
    MO 1-Year Stock Price Chart

    Eleven members of the Simply Wall St Community currently place Altria’s fair value between about US$48.08 and US$104.61 per share, reflecting wide differences in expectations. As you weigh these views, the recent FDA approval for on! PLUS pouches sits at the center of how future reduced risk product growth might influence Altria’s earnings power and its ability to keep funding shareholder returns.

    Explore 11 other fair value estimates on Altria Group - why the stock might be worth as much as 86% more than the current price!

    Build Your Own Altria Group Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Want Some Alternatives?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.